Telescope Innovations Corp · CSE:TELI
Telescope Innovations — Investor Presentation (November 2024)
16 slides from Telescope Innovations's investor presentation, November 2024
Slide 1: Driving innovation through intelligent automation
November 2024 Corporate Presentation Driving innovation through intelligent automation CSE : TELI OTCQB : TELIF Corporate Presentation November 2024 www.telescopeinnovations.com CSE : TELI OTCQB : TELIF Telescope Innovations Corp. | 1
Slide 2: Disclaimer
November 2024 Corporate Presentation Disclaimer The Presentation is intended for educational and informational purposes only and does not replace independent professional judgment. Statements of fact and opinions expressed are those of the participants individually. The information is not designed t
Slide 3: Telescope develops intelligent automation platforms that accelerate innovation
November 2024 Corporate Presentation Telescope develops intelligent automation platforms that accelerate innovation Telescope reduces R&D, manufacturing, and commercial deployment time and costs for the chemicals, pharmaceutical, and critical minerals industries Artificial Automation & Analytical Int
Slide 4: Global Demand for Lab Innovation
November 2024 Corporate Presentation Global Demand for Lab Innovation Major spending into intelligent automation to accelerate innovation $42B Global R&D investment Governments around the world are Chemicals in the chemicals sector incentivizing major new investments Industry in 20221 to resolve som
Slide 5: The Impact of Intelligent Automation
November August 2024 2024 Corporate Corporate Presentation Presentation The Impact of Intelligent Automation AI-guided decision making, automated experiments, and automatic analysis are reducing costs and accelerating the time from lab to market by 10 – 100x Conventional Discovery Drug Development &
Slide 6: A Specialized Growth Team
November 2024 Corporate Presentation A Specialized Growth Team Our management team combines internationally-recognized science acumen and a track record of value creation Values at Exit (USD) Scientific Achievements Value Creation History Grew and sold provider of analytical instrumentation for parti
Slide 7: The Telescope Business Model
November 2024 Corporate Presentation The Telescope Business Model Contract R&D Clients Industry Clients A scalable, Conducting contract R&D three-pronged revenue with strategic clients to solve specific industry problems generation model Telescope World-Class Contract R&D Science Team Revenue A decad
Slide 8: Our Product Portfolio
November 2024 Corporate Presentation Our Product Portfolio IP Portfolio Supported by a foundation of contract research, Telescope 3 patents; 1 proof-of-concept has entered global markets with a flagship product and has Patent I generated a significant pipeline of monetizable products Strategic Initiat
Slide 9: DirectInject - LC
November 2024 Corporate Presentation DirectInject - LC™ An intelligent, automated chemical analysis tool. DirectInject-LC™ accelerates chemistry research & reduces development costs. Accelerating research through intelligent automation Recurring Revenue Accessories, services, and software licenses p
Slide 10: Global Distribution Strategy
November 2024 Corporate Presentation Global Distribution Strategy Leveraging international GLOBAL DISTRIBUTION distribution partners to Telescope has signed a global distribution agreement with Mettler Toledo (NYSE: MTD), a global supplier of analytical precision instruments with US$3.8B (2023) acce
Slide 11: Self-Driving Labs
November 2024 Corporate Presentation Self-Driving Labs Telescope is developing self-driving labs SELF-DRIVING LABS that leverage robotics, analytical Accelerating the transition of technology, and AI control software to novel chemicals, materials, or rapidly optimize experiments processes from disco
Slide 12: Global Customer & Partner Network
November August 2024 2024 Corporate Corporate Presentation Presentation Global Customer & Partner Network Partnering with global enterprises to accelerate distribution, development, and R&D funding Contract Research Clients Pharmaceutical Funding & Academic & Product Development Partners Partners Pa
Slide 13: Telescope is positioned at an inflection point for growth
First Product Global MT Portfolio Product/ Lab Setup License Release (DILC) Distribution Distribution Expansion - SDL /Portfolio revenue November 2024 Corporate Presentation expansion Expansion 2022 2023 2024 2025 2026 2027 Telescope is positioned $15.1M at an inflection point for $12.6M growth among
Slide 14: The Telescope Executive Team
November 2024 Corporate Presentation The Telescope Executive Team Prof. Jason Hein Dr. Barry Sharpless Henry Dubina Dr. Jeff Sherman John Kirincic CTO & Director Senior Advisor CEO & Chairman CCO CFO Leads one of the largest academic 2-time winner of the Nobel Prize 35 + years experience in General
Slide 15: Capital Structure
November 2024 Corporate Presentation Capital Structure Telescope leverages AI, robotics, and Share Capitalization Dollar figures in CAD advanced data analysis to make Shares Outstanding MM 53.7 research faster, more precise, and more innovative Held by Directors/Officers % 25% A Globally-Scalable Int
Slide 16: Contact
Driving innovation through intelligent automation CSE : TELI OTCQB : TELIF Contact Investors@telescopeinn.com www.telescopeinnovations.com
Telescope Innovations — Investor Presentation (November 2024) on 6ix